Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 37 versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 37 versus TALWIN.
DURAGESIC-37 vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl binds to mu-opioid receptors, activating G-protein coupled receptor signaling, leading to inhibition of adenylate cyclase, decreased cAMP production, and modulation of ion channels (increased potassium efflux, decreased calcium influx). This results in reduced neuronal excitability, inhibition of nociceptive transmission, and altered pain perception. Additionally, fentanyl may interact with other opioid receptors (kappa, delta) with lower affinity.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
Initial: 25 mcg/hour transdermal patch applied every 72 hours. Titrate based on opioid tolerance. For opioid-naive patients: 12 mcg/hour patch.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
Terminal elimination half-life 20-27 hours (range 13-42 h) after transdermal removal; due to continuous absorption from skin depot, effective half-life is longer during patch wear.
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Primarily renal: 75% as metabolites (mostly norfentanyl) and <10% unchanged drug. Fecal: 9% via biliary elimination.
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic